Evolent Health (EVH) Stock Forecast & Price Target

$30.51

+0.16 (+0.53%)

(As of 09/6/2024 ET)

Evolent Health - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Buy
Based on 12 Analyst Ratings

Based on 12 Wall Street analysts who have issued ratings for Evolent Health in the last 12 months, the stock has a consensus rating of "Buy." Out of the 12 analysts, 12 have given a buy rating for EVH.

Consensus Price Target

$40.40
32.42% Upside

High Forecast	$46.00
Average Forecast	$40.40
Low Forecast	$31.00

According to the 12 analysts' twelve-month price targets for Evolent Health, the average price target is $40.40. The highest price target for EVH is $46.00, while the lowest price target for EVH is $31.00. The average price target represents a forecasted upside of 32.42% from the current price of $30.51.

Type	Current Forecast 9/8/23 to 9/7/24	1 Month Ago 8/9/23 to 8/8/24	3 Months Ago 6/10/23 to 6/9/24	1 Year Ago 9/8/22 to 9/8/23
Consensus Rating	Buy	Moderate Buy	Moderate Buy	Moderate Buy
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	12 Buy rating(s)	12 Buy rating(s)	11 Buy rating(s)	7 Buy rating(s)
Hold	0 Hold rating(s)	1 Hold rating(s)	1 Hold rating(s)	1 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$40.40	$42.00	$42.00	$46.56
Forecasted Upside	32.42% Upside	45.86% Upside	43.41% Upside	59.74% Upside

Get Evolent Health Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for EVH and its competitors with MarketBeat's FREE daily newsletter.

Ad Behind the Markets

⭕ [URGENT] Buy Alert just triggered

My absolute favorite stock just hit a critical "buy now" trigger price.

Click here for the ticker >>>

EVH Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

EVH Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Evolent Health Stock vs. The Competition

Type	Evolent Health	Computer and Technology Companies	S&P 500
Consensus Rating Score	3.00	2.64	2.51
Consensus Rating	Buy	Moderate Buy	Moderate Buy
Predicted Upside	32.42% Upside	204.80% Upside	11.36% Upside
News Sentiment Rating	Very Positive News	Neutral News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
8/27/2024	Truist Financial 1 of 5 stars	J. Singh Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$33.00 ➝ $33.00	+5.26%
8/26/2024	Royal Bank of Canada 4 of 5 stars		Reiterated Rating	Outperform ➝ Outperform	$42.00 ➝ $42.00	+25.60%
8/19/2024	JPMorgan Chase & Co. 3 of 5 stars		Boost Target	Overweight ➝ Overweight	$36.00 ➝ $45.00	+60.77%
8/9/2024	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Market Outperform ➝ Market Outperform	$34.00 ➝ $31.00	+48.11%
7/30/2024	Stephens Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Overweight ➝ Overweight	$42.00 ➝ $42.00	+75.95%
5/10/2024	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$44.00 ➝ $41.00	+70.41%
Get the Latest News and Ratings for EVH and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Evolent Health and its competitors with MarketBeat's FREE daily newsletter.
4/22/2024	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy	$40.00	+35.55%
3/1/2024	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Outperform	$45.00	+32.70%
1/9/2024	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Outperform
1/3/2024	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Overweight	$39.00	+17.21%
11/16/2023	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Outperform
10/16/2023	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy	$46.00	+64.29%
8/14/2023	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy ➝ Buy	$47.00	+65.03%
2/23/2023	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target		$40.00 ➝ $45.00	+31.31%
1/30/2023	Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform	$57.00 ➝ $59.00	+88.68%
1/6/2023	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target		$44.00 ➝ $51.00	+93.55%
11/18/2022	Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform	$52.00 ➝ $57.00	+138.89%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 09:48 PM ET.

EVH Forecast - Frequently Asked Questions

What is Evolent Health's forecast for 2024?: According to the research reports of 12 Wall Street equities research analysts, the average twelve-month stock price forecast for Evolent Health is $40.40, with a high forecast of $46.00 and a low forecast of $31.00.
Should I buy or sell Evolent Health stock right now?: 12 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Evolent Health in the last year. There are currently 12 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" EVH shares.
Does Evolent Health's stock price have much upside?: According to analysts, Evolent Health's stock has a predicted upside of 41.09% based on their 12-month stock forecasts.
Has Evolent Health been upgraded by Wall Street analysts recently?: Over the previous 90 days, Evolent Health's stock had 1 upgrade by analysts.
What analysts cover Evolent Health?: Evolent Health has been rated by research analysts at JMP Securities, JPMorgan Chase & Co., Royal Bank of Canada, Stephens, and Truist Financial in the past 90 days.
Do Wall Street analysts like Evolent Health more than its competitors?: Analysts like Evolent Health more than other "computer and technology" companies. The consensus rating for Evolent Health is Buy while the average consensus rating for "computer and technology" companies is Moderate Buy. Learn more on how EVH compares to other companies.